PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32441299-5	2020	Using well-defined computational methods, we identified Glecaprevir and Maraviroc (MVC) as the best inhibitors of SARS-CoV-2 Mpro.	glecaprevir	56-67	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	125-129	
33645457-5	2021	Current study, based on docking and extensive set of MD simulations, finds the combination of Elbasvir, Glecaprevir and Ritonavir to be a viable candidate for further experimental drug testing/pharmacophore design for Mpro.Communicated by Ramaswamy H. Sarma.	glecaprevir	104-115	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	218-222	
32441299-7	2020	Glecaprevir and MVC bind to the conserved residues of substrate-binding pocket of SARS-CoV-2 Mpro.	glecaprevir	0-11	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	93-97	
34986429-5	2022	Molecular dynamics (MD) simulations confirmed the stability of their Mpro complexes, with the MMPBSA binding free energy (DeltaGbind) ranging between -124 kJ/mol (glecaprevir) and -28.2 kJ/mol (velpatasvir).	glecaprevir	163-174	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	69-73	
34986429-8	2022	Glecaprevir and nelfinavir (DeltaGbind = -95.4 kJ/mol) appear to be the most effective antiviral drugs against Mpro.	glecaprevir	0-11	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	111-115